Alkermes

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Alkermes and other ETFs, options, and stocks.

About ALKS

Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL.

CEO

Richard F. Pops

CEORichard F. Pops

Employees

2,050

Employees2,050

Headquarters

Dublin, Dublin

HeadquartersDublin, Dublin

Founded

2011

Founded2011

Employees

2,050

Employees2,050

ALKS Key Statistics

Market cap

7.68B

Market cap7.68B

Price-Earnings ratio

50.02

Price-Earnings ratio50.02

Dividend yield

—

Dividend yield—

Average volume

2.49M

Average volume2.49M

High today

$46.94

High today$46.94

Low today

$45.01

Low today$45.01

Open price

$45.33

Open price$45.33

Volume

3.23M

Volume3.23M

52 Week high

$46.94

52 Week high$46.94

52 Week low

$25.17

52 Week low$25.17

Stock Snapshot

As of today, Alkermes(ALKS) shares are valued at $45.70. The company's market cap stands at 7.68B, with a P/E ratio of 50.02.

During the trading session on 2026-06-22, Alkermes(ALKS) shares reached a daily high of $46.94 and a low of $45.01. At a current price of $45.70, the stock is +1.5% higher than the low and still -2.7% under the high.

Trading volume for Alkermes(ALKS) stock has reached 3.23M, versus its average volume of 2.49M.

The stock's 52-week range extends from a low of $25.17 to a high of $46.94.

ALKS News

TipRanks 13h

Alkermes price target raised to $50 from $42 at TD Cowen

TD Cowen raised the firm’s price target on Alkermes (ALKS) to $50 from $42 and keeps a Buy rating on the shares. The firm updated its model after attending the...

Simply Wall St 14h

Alkermes Stock Near Fair Value After Positive Alixorexton Phase 2 Results - simplywall.st

...

TipRanks 1d

Alkermes Elevated to $50 Price Target as Orexin Leadership and Alixorexton Pipeline Drive Buy Rating

Analyst Joseph Thome from TD Cowen maintained a Buy rating on Alkermes and increased the price target to $50.00 from $42.00. Claim 55% Off TipRanks Unlock power...

Analyst ratings

81%

of 16 ratings

Buy

81.3%

Hold

18.8%

Sell

More ALKS News

TipRanks 5d

Alkermes Price Target Reaffirmed at $43 as Encouraging Vibrance-2 Data Support Neutral Stance

H.C. Wainwright analyst Douglas Tsao maintained a Hold rating on Alkermes today and set a price target of $43.00. Claim 55% Off TipRanks Unlock powerful investi...

TipRanks 5d

Alkermes reports ‘positive results’ from Vibrance-2 Phase 2 study of alixorexton

Alkermes (ALKS) announced “detailed positive results” from the Vibrance-2 phase 2 dose-ranging study evaluating alixorexton in patients with narcolepsy type 2....

People also own

Based on the portfolios of people who own ALKS. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.